Deep sequencing of breakthrough infections from the AMP trials shows that prophylactic VRC01 selected for low-frequency HIV ...
A randomized phase 2a trial found the SARS-CoV-2 monoclonal antibody AER002 safe but ineffective for Long COVID overall, ...
The initiation of the Phase 1/2a clinical trial will represent a key milestone in advancing a first-in-class HMGB1-targeted immunomodulatory antibody for patients with frontotemporal lobar ...
Therapeutic antibodies have already revolutionized the management of many cancers, as well as autoimmune and inflammatory diseases. Their great strength? Their ability to pinpoint a biological target ...
FairJourney Bio’s Maria Gonzalez Pajuelo reflects on her early work with nanobodies, the potential of single-domain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results